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Abstract:  33 
Presurgical studies allow study of the relationship between mutations and response of 34 
estrogen receptor positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been 35 
limited to small biopsies. Here in Phase I of this study, we perform exome sequencing on 36 
baseline, surgical core-cuts and blood from 60 patients (40 AI treated, 20 Controls). In poor 37 
responders (based on Ki67 change) we find significantly more somatic mutations than good 38 
responders. Subclones exclusive to baseline or surgical cores occur in approximately 30% of 39 
tumours. In Phase II we combine targeted sequencing on another 28 treated patients with 40 
Phase I. We find six genes frequently mutated: PIK3CA, TP53, CDH1, MLL3, ABCA13 and FLG 41 
with 71% concordance between paired cores. TP53 mutations are associated with poor 42 
response. We conclude that multiple biopsies are essential for confident mutational 43 
profiling of ER+ breast cancer and TP53 mutations are associated with resistance to 44 
oestrogen deprivation therapy. 45 
  46 
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Introduction 47 
Assessment of somatic mutations is becoming increasingly important for the 48 
management of cancer patients but molecular heterogeneity occurs across many tumors1. 49 
This variability is of particular interest in relation to the clonal evolution of individual 50 
malignancies but it also poses a severe analytical challenge in terms of the degree to which 51 
the whole tumour mutational repertoire is represented by limited biopsy material.  52 
In breast cancer there is major interest in the use of pre-surgical studies for assessing 53 
the biological effect of therapeutic agents2, including the impact that the agents may have 54 
on the responsiveness of sub-populations and the emergence of subclones resistant to 55 
therapy. However, such studies inevitably depend on analyses of sequential, usually core-56 
cut biopsies that often sample <1% of the tumour mass and may therefore provide limited 57 
representation of the tumour genotype. 58 
Breast cancer is the most common malignancy in females in western countries and 59 
oestrogen receptor positive (ER+) tumours contribute about 60-75% of the disease3. 60 
Aromatase inhibitors (AIs) are the most effective agents in post-menopausal woman 61 
reducing recurrence rates in primary breast cancer patients by c.50%4. These agents inhibit 62 
aromatase throughout the body by >97% and suppress plasma oestrogen levels to 63 
undetectable levels5. However, these therapies are not effective in every patient. Hence, 64 
identifying the role that mutations play in de novo resistance to AIs is an important clinical 65 
research goal. 66 
One large pre-surgical study, PeriOperative Endocrine Therapy - Individualising Care 67 
(POETIC) trial, randomized 4,486 patients to receive two weeks’ non-steroidal AI or no 68 
treatment prior to surgery2. Biopsies were collected at diagnosis and at surgery to correlate 69 
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molecular alterations in the tumours with their antiproliferative response to an AI. This 70 
provides the opportunity to identify DNA alterations that are of biological interest in 71 
relation to oestrogen responsiveness and of potential clinical importance in relation to AI 72 
use6. Like other pre-surgical studies, POETIC is potentially affected by within-tumour 73 
heterogeneity. The control group of POETIC (no pre-surgical treatment) allows us to study 74 
discrepancies between repeat biopsies from the same patients and to evaluate the 75 
molecular heterogeneity within the tumours. 76 
In Phase I of the current study we conduct whole exome analysis followed by 77 
capture-probe validation of baseline and surgical core-cut biopsies and of whole blood DNA. 78 
We select patients from the control group and treated patients at the extreme ends of the 79 
Ki67 response spectrum to study. On the exome-wide mutational profile we find a 80 
significantly higher mutational load in poor responding patients indicative for multiple 81 
resistance mechanism. Over 2 weeks’ of treatment we only find minor effects on the 82 
mutational profile in terms of mutational load and variant allele fractions. In about 30% of 83 
the tumours we detect intra-tumoural heterogeneity with subclones exclusively to one of 84 
the core-cut.  In Phase II we perform capture-probe sequencing of baseline and surgical 85 
core-cut biopsies and whole blood DNA on additional patients. We concentrate our analysis 86 
on mutations in 77 breast cancer genes, for which the entire coding-sequence was added to 87 
the capture panel. Through integrating the data from Phase I and II we find a reduced 88 
suppression of Ki67 within the poor responder group for TP53-mutated tumours and 89 
therefor a potential marker for poor response to oestrogen deprivation therapy. We show 90 
concordant detection of the mutation status of frequently mutated genes in 76% of the 91 
cases. Together with the subclonal analysis we conclude that limited tumour material from 92 
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core-cuts complicate mutational profiling of ER+ breast cancer. Multiple biopsies are 93 
required for confident mutation calling, especially for heterogeneous tumours. 94 
 95 
96 
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Results  97 
Clinical Cohort 98 
When Phase I was initiated 148 patients from POETIC (CRUK/07/015) had paired 99 
baseline and surgical (2 week) RNAlater preserved samples available. To focus on a 100 
comparison between particularly poor responders and good responders, we excluded 101 
treated patients with Ki67 decrease between 60 and 75% (n=34, Methods). After quality 102 
assessments, we found 60 eligible sample pairs. Our goal was to choose equal numbers of 103 
good and poor responders, but in these pairs only 15 poor responders were found. 104 
Therefore, all 25 available good responders were included for a set of 40 treated patients. 105 
Together with the 20 pairs from the POETIC untreated control group these constituted the 106 
60 patient cohort of Phase I (Fig. 1a and Supplementary Fig. 1). The patient demographics of 107 
samples from Phase I are described in Supplementary Table 1. 108 
To increase the statistical power to examine common events in AI-treated patients 109 
Phase II was subsequently conducted including sample pairs that had become available 110 
during continual conduct of the POETIC trial. From 108 available pairs of RNAlater preserved 111 
samples, we excluded Controls (n=19) and in keeping with Phase I we excluded samples not 112 
falling into either the good or poor responder category (n=19). All 18 available poor 113 
responding patients were retained even if one sample of the pair did not meet our criteria 114 
(12 pairs, 6 singles) together with 10 good responders paired samples selected based on 115 
when they were received first in chronological order (Fig. 1b).  116 
The demographics of all 86 patients in this study are described in Table 1. 117 
 118 
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Mutation discovery in phase I of the study 119 
Whole exome sequencing (WES) was performed on tissues at baseline and at surgery 120 
and on blood from 60 patients (180 samples in total) for initial mutation discovery. This 121 
achieved a median coverage of 38x (germline 39x, tumour 37x; Supplementary Data 1); 11 122 
tumour samples including both from one patient (P033) were excluded due to low coverage. 123 
We identified a total of 6,910 somatic mutations in the remaining tumour samples from 59 124 
patients. 125 
 126 
Mutation validation in phase I of the study 127 
To validate the mutations from WES we performed targeted re-sequencing at higher 128 
depth on all 59 patients (excluding 11 tumour samples and one blood from patient P033, 129 
168 samples in total) from above (Supplementary Fig. 2). Therefore, we designed a capture-130 
probe panel covering all potential somatic mutations discovered from WES. Additionally, the 131 
entire coding region of 77 previously described breast cancer related genes were added to 132 
the panel (Supplementary Table 2). Seven samples attained low coverage, however 6 were 133 
sequenced successfully a second time (with samples from Phase II, P003 surgery had to be 134 
excluded, mean coverage of 7x). The remaining 167 samples had median coverage 105x 135 
(germline 110x, tumour 100x; Supplementary Data 1). Of these, 52 were baseline and 56 136 
were surgical samples consisting of 49 pairs: 17 Control, 11 poor and 21 good responder 137 
pairs (Table 2). 138 
The targeted re-sequencing validated 4,232 somatic mutations across the 59 139 
patients that were classified as tier 1 (variants in the coding regions of annotated exons, 140 
canonical splice sites, and RNA genes). Without counting identical mutations in paired 141 
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samples the number of validated mutations was 6,283 mutations across 108 tumour 142 
samples (Supplementary Fig. 3 and Supplementary Data 2). These affected 3,388 genes; the 143 
majority of mutations were missense (63%) or silent (23%) (Fig. 1c). The mean number of 144 
mutations per patient with paired exome-sequencing was 79.5 (median 49, interquartile 145 
range, 33.0 to 91.5, Fig. 1d). 146 
Two patients were outliers based on their low mutation count (≤8 mutations in both 147 
baseline and surgical samples) in the target area. There were two other pairs of samples 148 
with extreme differences in their mutation counts between baseline and surgery: 1 vs 407 149 
(P035, Control) and 86 vs 596 (P045, good responder). To exclude sequencing bias, these 150 
samples were sequenced a second time to over 200x median combined coverage per 151 
sample. The plot of variant allele fractions (VAFs) between the two runs showed high 152 
correlations (r=0.85-0.92, Pearson correlation) between the replicates indicating high 153 
reproducibility (Supplementary Fig. 4c-f). Despite the higher coverage, many mutations 154 
were found in only one or other sample of these pairs (Supplementary Fig. 4a-b), suggesting 155 
that these discordances may have been due to normal tissue contamination. This is 156 
supported by tumour purity estimation on WES data of these samples (Supplementary Fig. 157 
4).  158 
 159 
Mutational load from phase I samples 160 
For samples in Phase I all potential somatic mutations discovered by WES were 161 
added to the capture-panel for validation. This allowed an evaluation of their exome-wide 162 
mutational load (that is their total number of mutations). At baseline and at surgery, there 163 
was a significant higher mutational load in samples from poor than good responders 164 
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(median 62.0 vs 33.5, p=0.047, Fig. 2a and median 56.5 vs 29.0, p=0.022, Fig. 2b, Mann-165 
Whitney test). Controls showed similar mutation numbers to good responders. There was 166 
no significant difference between baseline and surgical samples in mutation counts within 167 
the good responders, poor responders or Control (Fig. 2d). However, considering all 32 168 
treated pairs as a group there was a minor but statistically lower median count after 169 
treatment (median baseline 43.5 vs. surgery 37.0, median of differences -2, p=0.019, 170 
Wilcoxon signed-rank test). This significance was retained but weaker after exclusion of the 171 
two patients with extreme differences (P035 and P045) from the analysis (p=0.034). Given 172 
that the treatment-related differences between baseline and surgery were minor, we 173 
merged the mutations in each of the pairs of samples and created a count of unique 174 
mutations per tumour giving a value for 49 tumours. Similar to the comparisons described 175 
above and shown in Fig. 2a and b, we found that poor responders had significantly more 176 
mutations than good responders (median 104 vs 41, p=0.021, Fig. 2c, Mann-Whitney test). 177 
We compared the VAFs of mutations between the baseline and surgical sample in all 178 
tumours and observed correlations up to 0.86 (Pearson correlation, Supplementary Fig. 5). 179 
The VAFs of mutations found in both samples of a pair were significantly lower in surgical 180 
than baseline samples for good (median baseline 29.2 vs surgery 26.3, p<0.001, Wilcoxon 181 
signed-rank test) and poor responders (27.0 vs 24.7, p<0.001) but not Control pairs (27.0 vs 182 
26.5, p=0.573, Fig. 2e).  183 
 184 
Mutational clusters from phase I of the study 185 
We compared the VAFs between baseline and surgical samples to identify 186 
mutational clusters which may represent subclones using SciClone7 (Methods). SciClone 187 
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analysis was possible in 40 cases: 11 Controls, 20 good and 9 poor responders 188 
(Supplementary Fig. 6-8). The median number of identified clusters was 3; the maximum 189 
number was 6. Five examples are shown in Fig. 3 selected based on a relatively large 190 
number of clusters. We did not perform statistical comparisons of the cluster number 191 
between the responder groups because of the small sample size. Visual inspection and 192 
comparison of SciClone plots did not reveal differences in the degree of heterogeneity 193 
between good and poor responders with both groups having patients showing low and high 194 
heterogenic sample pairs. In most pairs, the clusters were represented in both samples of 195 
the pair (e.g. P007, P014 and P039, Fig. 3). In about 30% there was clear representation of 196 
one or more clusters in only one sample of the pair (e.g. P002 and P046, Fig. 3). These 197 
exclusive clusters were found in both baseline and surgical samples of all three groups. In 198 
these cases, we still found that at least one cluster, usually the one with mutations having 199 
the highest VAFs in both samples, which was present in both samples of the pairs.  200 
 201 
Mutation detection in phase II 202 
The capture-probe panel from Phase I was used on additional samples from 28 203 
patients (Fig. 1b) and 8 samples from Phase I where WES was unsuccessful, but enough DNA 204 
was available. Sequencing of one sample from Phase I was unsuccessful. In concordance 205 
with the analysis in Phase I, we excluded germline mutations based on their sequenced 206 
matched blood. The median coverage for these samples was 91x (germline 103x, tumour 207 
76x, Supplementary Data 1). One patient was excluded from further analysis because of a 208 
different SNP profile (P085, Supplementary Fig. 9). The mutation count for the remaining 27 209 
patients without prior WES discovery was inevitably much lower than for Phase I samples 210 
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(mean 6.4, median 5.0 mutations per patient, interquartile range, 3.0 to 6.0, Supplementary 211 
Fig. 10) as only few mutations in the Phase II were found outside the 77 breast cancer 212 
related genes. As for Phase I we only used tier 1 mutations for further analyses 213 
(Supplementary Data 3). 214 
 215 
Frequently mutated genes 216 
We combined the mutation data from Phase I and II to identify frequently mutated 217 
genes in the samples of the 86 patients in our dataset (Table 2). Six of the 77 breast cancer 218 
related genes were mutated in 10% or more of the patients. In decreasing frequency these 219 
were PIK3CA (37%), TP53 (26%), CDH1 (14%), MLL3 (14%), ABCA13 (12%) and FLG (10%). 220 
The top three genes are also the most frequently mutated genes in ER+, post-menopausal 221 
breast cancers in TCGA8 (Supplementary Table 3). The frequency of mutations in PIK3CA and 222 
CDH1 was very similar to the TCGA cohort, but the other four genes showed higher 223 
frequency in our data set, especially ABCA13 with 12% compared with 4% in TCGA. We 224 
assessed whether good or poor responders were significantly associated with mutations in 225 
ABCA13 or other frequently mutated genes, but we did not find such an association (6/27 vs 226 
2/31, p=0.258, Fisher’s exact test, not shown for other genes). Apart from the top three 227 
frequently mutated genes (PIK3CA, TP53 and CDH1) only GATA3, RYR2 and MAP3K1 are 228 
mutated in more than 5% of patients in TCGA (9%, 6% and 9% of tumours, respectively). For 229 
these we found similar frequencies in our set (7% 6% and 5%, respectively). The most 230 
recurrent amino acid changes in our patients were H1047R (in 14 patients) followed by 231 
E545K (5 patients) in PIK3CA. For the majority of the frequently mutated genes missense 232 
was the most common amino acid change. Exceptions were CDH1 with predominantly 233 
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frameshift mutations (12 frameshift, 1 missense and 1 nonsense) and MLL3 with nonsense 234 
mutations (14 nonsense, 4 missense and 1 frameshift). 235 
There was at least one mutation in a frequently mutated gene in 53 of the 77 pairs 236 
(Fig. 4). In all but 22 cases, the mutations in frequently mutated genes were identical for 237 
both samples of the pair giving a 54% concordance. In these pairs, 28 sites were identified 238 
as discordant, although 14 of these showed a measurable frequency (but not reaching 239 
statistically significance) in the other sample of the pair. The other discordant sites showed 240 
no frequency in the other samples of the pair, but all had a coverage >50x. The mutation 241 
status per patient (identical mutations or wild type) of the 6 frequently mutated genes was 242 
concordant in 71% of the complete set of 77 pairs. For individual genes, the concordance 243 
was higher for PIK3CA (3/27 discordant/concordant, 90%) and TP53 (7/15, 68%) compared 244 
to the less frequently mutated genes ABCA13 (6/2, 25%) and FLG (6/4, 40%). Also the VAF of 245 
mutations in PIK3CA (median baseline/surgery 30.3%/28.8%) and TP53 (33.3%/33.1%) were 246 
generally higher than for ABCA13 (15.5%/11.1%) and FLG (12.3%/13.5%), which were lower 247 
than the overall median of 25.7%. 248 
Mutations in breast cancer driver genes listed by DriverDB9 were found in 65 of the 249 
77 sample pairs with a median of 2 driver gene mutations per sample (Supplementary Table 250 
4). In 25 pairs all driver mutations were identified in both samples. Twelve pairs had none of 251 
their driver mutations shared, resulting in an overall concordance of 54%. 252 
 253 
TP53 and HER2 254 
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Non-functional TP53 can lead to DNA damage accumulation10. Therefore, we 255 
compared the mutational load of samples from Phase I by their TP53-mutation status and 256 
found a significantly higher load for mutated samples (median WT 37 vs mutant 64.5, 257 
p=0.017, Mann-Whitney test). For samples from Phase I the mutational load correlated 258 
weakly with Ki67 level at baseline (r=0.31, p=0.02 Spearman correlation), but a moderate 259 
correlation was found for the treated samples at surgery (r=0.40, p=0.01, Fig. 5a). Poor 260 
responders and TP53 are both associated with higher mutational load: using the combined 261 
set of patients (Phase I and II), we hypothesized that poor responders were more likely to 262 
have a TP53 mutation compared with good responders, but this hypothesis was rejected 263 
(10/23 vs 8/25, p=0.8, Fisher’s exact test). However, we found a significantly higher Ki67 264 
baseline level for TP53 mutated samples (Supplementary Fig. 11) for both good (median WT 265 
16.9 vs. mutated 36.7, p=0.020, Mann-Whitney test) and poor responders (median WT 15.9 266 
vs. mutated 32.3, p=0.006). This difference was lost after treatment for the good, but 267 
persisted for poor responders (median WT 10.3 vs. mutated 28.7, p=0.011, Fig. 5b).  268 
In HER2+ and HER2- tumours the median mutational load was 64 and 42, 269 
respectively (p=0.180, Mann-Whitney test).  There was a higher than expected HER2+ rate 270 
amongst the control samples (35% in this dataset, expected rate in an ER+ population is 271 
~10%11).  272 
A significant decrease in the cellularity between baseline and surgery samples was 273 
found for good, but not poor responders or Controls (Supplementary Fig. 12) as reflected by 274 
the total number of cells per high-powered field in the Ki67 analysis. The type of biopsy 275 
taken at surgery (core-cut or resection) did not differ statistically between any responder 276 
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groups and did not explain differences in cellularity for good and poor responders 277 
(Supplementary Fig. 13). 278 
279 
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Discussion  280 
Our primary goal was to identify DNA changes that relate significantly to the 281 
response of ER+ breast cancer to short-term oestrogen deprivation using AIs. Although the 282 
pre-surgical setting was ideal for this purpose, little is known about the true, as opposed to 283 
theoretical, impact of tissue heterogeneity on mutational profiling from the small tumour 284 
biopsies that are available for mutation profiling studies of clinical material. Our data on 285 
reproducibility are critical for a valid understanding of the current study and the many other 286 
studies of this type.  287 
Very few data have been published on the genomic heterogeneity of multiple cores 288 
taken from the same breast tumour. The correlations of VAFs from two samples from five 289 
breast tumours reported by Ellis et al6 (r=0.74 to r=0.94) were consistent with the majority 290 
of comparisons in the current analysis but in our larger set the correlations were much 291 
lower for some of our cases (Supplementary Fig. 5). Preliminary data was recently reported 292 
on 13 patients with multiple (7 to 17) spatially separated samples of primary breast cancer 293 
(ER+ and other types) – heterogeneity was observed within the samples even of cancer 294 
driver mutations12. Yates et al13 reported heterogeneity in 8 out of 12 treatment-naive 295 
breast cancers based on 8 spatially separated biopsies from each tumour.  296 
Most pairs in our study showed several clusters (potential subclones) present in both 297 
samples, but in about 30% of the cases we also found sample pairs with several clusters 298 
being exclusive to either sample and therefore spatially separated in the same tumour. 299 
However, these pairs shared at least one cluster, usually the one with the highest VAFs, 300 
indicative of a common founding clone with driving cancer mutations14.  Although clusters 301 
exclusive to one sample were often present in a small proportion of sequenced cells, each 302 
subclone potentially has different adaptive properties and might become the dominant 303 
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clone due to selection from treatment15,16. Clusters disappearing or becoming more 304 
prominent in the treatment group could be indicative of such a selection. In our data it is 305 
unlikely that the exclusive clusters occur due to selection from AI treatment since we found 306 
exclusive clusters in the Control group as well and AI treatment had a very modest effect on 307 
cellularity in the 2 weeks of this study. 308 
Reduced heterogeneity was found after 6 months of AI treatment17. In our data after 309 
much shorter time, we found that the number of mutations and the VAFs were slightly but 310 
statistically significantly lower in the surgical samples of treated compared with control 311 
patients, possibly indicating a modest treatment effect. Such a small effect was consistent 312 
with the slow rate of clinical response of tumours to endocrine therapy. This is dependent 313 
on cytostasis and not enhanced cell death such that tumour shrinkage is rarely apparent 314 
over a 2 week time period. In the good responder group, we noted that a minor loss of 315 
cellularity occurred over the 2-week period based on field counts of nuclei. Reduced 316 
cellularity could conceivably make the microdissection we carried out for all tissue sections 317 
prior to genomic analysis more difficult and thereby lead to greater non-malignant cell 318 
contamination potentially reducing the sensitivity to detect variants. These results are 319 
therefore consistent with the slightly decreased number of mutations in the surgical 320 
samples being at least in part an artefact of the lower malignant cell purity in the dissected 321 
material from the surgical samples. Given that the median loss between baseline and 322 
surgical samples from AI-treated patients was only 2 mutations we rationalized that surgical 323 
samples even from these were sufficiently unaffected by treatment to be acceptable as 324 
representative of the untreated state. Merging mutation data from baseline with surgical 325 
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samples including those from treated patients should provide more comprehensive 326 
information on the mutational landscape of a tumour than single cores. 327 
Modest coverage for WES might have missed mutations with low VAF, especially 328 
mutations present at very low frequency in both samples of a pair. These mutations 329 
therefore could not be integrated in the panel and subsequently are missing in the final set 330 
of mutations and subclones. To maximise the number of mutations in the capture-panel, we 331 
used the union of several variant callers on the WES data to detect potential somatic 332 
mutations. Further, we included the entire coding sequencing of 77 breast cancer related 333 
genes in the panel to be able to detect mutations in these independent of the discovery 334 
step. We used the same capture-probe panel for additional samples in Phase II of this study. 335 
Unlike Phase I, the panel was not specifically designed to validate mutations found in the 336 
discovery stage. Therefore, in Phase II far fewer mutations per sample were found outside 337 
the 77 breast cancer related genes, emphasizing the individuality of the mutational profile 338 
of each breast cancer tumor18. For the combined set of samples from Phase I and II we 339 
therefore exclusively concentrated on the 77 breast cancer genes present on the targeted-340 
panel and did not perform analyses based on mutation count or subclonality with these.  341 
As expected, the most frequently mutated genes across the 86 patients were the 342 
breast cancer driver genes PIK3CA and TP536. CDH119 and MLL320 are also frequently 343 
mutated genes known to be linked to breast cancer. The genes FLG and ABCA13 are less 344 
studied, but FLG was shown to be amplified in a subset of breast cancers21. The frequency of 345 
patients with mutations in ABCA13 was about three-fold higher compared to post-346 
menopausal ER+ breast cancer tumours from TCGA8. A reason for this could be the selection 347 
of patients based on good and poor response; however, we did not find significant 348 
18 
 
differences between good and poor responders in terms of the mutation frequency of 349 
ABCA13 or other frequently mutated genes. GATA3 was not in the top list of frequently 350 
mutated genes, but its frequency was similar to that in TCGA. It was suggested that GATA3 351 
mutations might be a positive prediction marker for AI response based on Ki67 decline6. Our 352 
data cannot support this finding, but the statistical power with 6 mutated patients is low.  353 
We saw low correlations for some samples based on the VAF values of all mutations 354 
in a sample pair. However, the mutation status of frequently mutated genes in the present 355 
data was found to be consistent within pairs in 76% of cases. Thus in a majority of cases the 356 
profile of mutations in the genes would be represented by one core. However, in about one 357 
in four patients this would not be the case and a single core-cut would have missed a 358 
potentially important gene mutation. We noted higher discordance and lower VAFs for 359 
mutations in less frequently mutated genes (ABCA13 and FLG). This suggests that these 360 
mutations are subclonal, but might have important functions upon selective pressure. 361 
However, mutations at lower VAF are also more difficult to detect, which might in part 362 
explain the lower concordance for these mutations. We also analysed the concordance for 363 
the more numerous driver genes listed in DriverDB and we found a lower concordance of 364 
54% between all pairs. 365 
To study the impact of mutational profile on response to AI treatment, patients at 366 
the extreme ends of the Ki67 response spectrum were chosen as poor or good responders 367 
from the available patient sample set. Change in Ki67 after 2 weeks is a validated end-point 368 
for benefit from adjuvant endocrine therapy while the value of Ki67 after 2 weeks is 369 
prognostic for recurrence-free survival22. Ellis et al6 related the mutational profile to 370 
resistance to AI in 77 patients using Ki67, defining resistance as on treatment Ki67 > 10% 371 
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irrespective of starting level. According to this definition four patients in our data set would 372 
have been categorized as good responders despite exhibiting a minimal Ki67 decrease. 373 
Nonetheless, there is generally good concordance between these two definitions and the 374 
major conclusions on AI resistance from the current study and the Ellis study are similar. 375 
We excluded 7% of patients who were categorized as poor responders according to 376 
Ki67 decrease due to a lack of E2 suppression. It is not known whether this was due to poor 377 
compliance or poor pharmacologic response but whichever is the case this highlights the 378 
importance of measuring primary pharmacological response to avoid intensive molecular 379 
investigation of tumours for mechanisms of resistance when the expected pharmacological 380 
perturbation is absent. 381 
The relatively low frequency of mutations in most genes in primary breast cancer 382 
means that large studies are required to define reliable associations with 383 
response/resistance to therapy even in pre-surgical studies such as POETIC where biological 384 
response is measurable in all treated patients (in contrast to adjuvant therapy). 385 
Nonetheless, we found a reduced suppression of Ki67 for TP53-mutated tumours within the 386 
poor responder group, which supports the finding by Ellis et al6 who reported a greater 387 
suppression of Ki67 by letrozole in wild type than TP53-mutated tumours. This indicates at 388 
least in part that TP53 mutations are a marker for poor response to AI in addition to being a 389 
marker for poorer outcome for ER+ breast cancer. We also found a significant association of 390 
mutated TP53 with increased mutational load. For TP53 this is consistent with it being an 391 
important DNA repair gene, malfunction of which may lead to general genomic instability 392 
and an increase in mutations. The association of these factors with high mutational load was 393 
recently reported by Haricharan et al23.  394 
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It could be expected that poor responders to endocrine therapy might exhibit 395 
greater genomic heterogeneity given its potential to provide multiple pathways of 396 
resistance, a hypothesis supported by the larger number of mutations found in poor 397 
responders in this study. The clear presence of subclonality and multiple driver mutations in 398 
some of these early breast tumours does indicate the potential for some subclones to be 399 
selected preferentially during hormonal treatment and to drive the clinical regrowth of a 400 
partially responsive tumour. Identification of such subclones or mutations requires further 401 
studies on a later time point when the effect of treatment would be greater than that at two 402 
weeks. 403 
In conclusion, this study demonstrates that multiple subclones are present even in 404 
early ER+ breast cancer. In most cases the subclones and their constituent mutations are 405 
represented in different core-cuts from the same tumour but in about 30% of the tumours 406 
mutations are exclusive to one of the core-cuts. Increased mutational load is associated with 407 
poorer antiproliferative response to AI possibly driven by mutations in TP53.  408 
409 
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Methods 410 
Patients and tissues 411 
The design and goals of the POETIC trial (CRUK/07/015) have been published2. In 412 
brief, post-menopausal patients with primary ER and/or PgR-positive (according to local 413 
testing) breast cancer in over 120 centres across the UK were randomized 2:1 to receive or 414 
not receive an AI (anastrozole 1mg/d or letrozole 2.5mg/d) for a four-week period starting 415 
two weeks prior to surgery.  416 
Core-cut biopsies (14-gauge) and either core-cuts or part of the excision sample 417 
were collected at baseline and surgery, respectively, and fixed in formalin. Additional core-418 
cuts were collected into RNAlater (Qiagen) at both time points. Whole blood was collected 419 
for germline DNA analysis, baseline and surgical plasma for estradiol analysis. 420 
The trial was approved by the NRES Committee London - South East. All patients 421 
gave informed consent for DNA sequencing. 422 
 423 
Biomarker analyses 424 
Ki67% staining (MIB-1 clone code n. M7240, DAKO UK Ltd; working dilution 1:40) 425 
was the primary biomarker end-point for the POETIC trial and was centrally analysed on all 426 
formalin-fixed samples using a single protocol (either core-cut in FFPE or excision specimens 427 
in FFPE) as previously described22. All staining was performed on a Dako autostainer using 428 
strict adherence to a single staining protocol. Hematoxylin and eosin (H&E) staining was 429 
used to exclude samples with low tumour purity (<40%).  430 
HER2 status was measured locally using immunohistochemistry and/or in situ 431 
hybridization24. Biomarker results are shown in Supplementary Table 5.  432 
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ER expression of baseline specimens was measured by immunohistochemistry (6F11 433 
clone code n. NCL-L-ER-6F11, Leica Biosystems Ltd; working dilution 1:50) on formalin-fixed 434 
samples25. Patients were excluded from this sub-study if they were described as ER negative 435 
(< 1% positive staining of tumour nuclei). 436 
Cellularity was measured by 10x10mm eye-piece graticule with 40x objective 437 
graticule. Nuclei were counted within the grid of at least 5 fields and the mean values from 438 
these measurements were used.  439 
Patients with unsuppressed estradiol upon treatment were excluded. 440 
 441 
Sample selection 442 
In Phase I samples were selected with the aim of having equal numbers of control 443 
patients, definite poor responders defined as having a Ki67 decrease of <60% between 444 
baseline and surgery and good responders with >75% Ki67 decrease. The definition of good 445 
responders was selected as being above the mean Ki67 reduction to anastrozole after two 446 
weeks26. Patients with Ki67 decrease between 60 and 75% were excluded to create an 447 
efficient design that focused on the extremes of the range of Ki67 responses. Treated 448 
patients not showing suppressed post-menopausal levels of plasma estradiol and those with 449 
central ER <1% were excluded. For Phase II only treated samples were selected. 450 
 451 
 452 
DNA extraction 453 
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DNA was extracted from RNAlater preserved diagnostic (baseline) and surgical 454 
(surgery) 14-gauge core-cut samples and peripheral blood.  455 
At least eight unstained eight-micron sections were taken from core-cuts embedded 456 
in OCT (Cryo-M-Bed, Bright Instruments, UK). Sections were stained with Nuclear Fast Red 457 
(0.1% (w/v)) and when necessary needle microdissection was used to achieve >60% pure 458 
tumor cells) using an adjacent haematoxylin and eosin-stained section as a guide. DNA was 459 
extracted from the sections using the DNeasy Tissue and Blood Kit (Qiagen) and from blood 460 
using the EZ1 system (LifeTechnologies). 461 
 462 
Exome sequencing for discovery 463 
Cavitation (adaptive focused acoustics, Covaris) was used to fragment the samples. 464 
The automated libraries were generated with in-house Illumina kits at Washington 465 
University, MO, with reagents supplied by NEB and indexed via PCR. LucigenDNATerminator 466 
Kit (end repair), NEB Klenow (Adenylation), NEB Quick Ligase (ligation, Illumina's 467 
Multiplexing Adapters), NEB Phusion (PCR enrichment, libraries were indexed via PCR 468 
(PCR1.0, PCR2.0 and index primers), AMPure beads were used for enzymatic purification 469 
and size selection). Manual libraries were generated with KAPA Library Preparation with 470 
standard PCR library amplification (KK8201) and libraries were indexed during ligation with 471 
TruSeq LT adaptors.  LabChip GX was used for library quantitation as well as quality control. 472 
Size selection was conducted using AMPure beads. 10 libraries were pooled pre-capture.  473 
Each library pool was captured using NimblegenSeqCap EZ Human Exome Library v3 (with 474 
requisite SeqCap EZ hybridisation and wash kits) and sequenced on two lanes of the 475 
IlluminaHiSeq 2000 with v3 chemistry (2x100bp).  476 
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Sequence data was aligned to reference sequence build GRCh37-lite-build37 using 477 
bwa version 0.5.927 (params: -t 4 -q 5) then merged using picard version 1.46 478 
(http://picard.sourceforge.net), then deduplicated using picard version 1.46. 479 
SNVs were detected using the union of three callers: 1) samtools version r96328 480 
(params: -A -B) intersected with Somatic Sniper version 1.0.229 (params: -F vcf -q 1 -Q 15) 481 
and processed through false-positive filter v1 (params: --bam-readcount-version 0.4 --bam-482 
readcount-min-base-quality 15 --min-mapping-quality 40 --min-somatic-score 40) 2) VarScan 483 
version 2.2.630 filtered by varscan-high-confidence filter version v1 and processed through 484 
false-positive filter v1 (params: --bam-readcount-version 0.4 --bam-readcount-min-base-485 
quality 15 --min-mapping-quality 40 --min-somatic-score 40), and 3) Strelka version 0.4.6.231 486 
(params: isSkipDepthFilters = 1). 487 
InDels were detected using the union of 4 callers: 1) GATK somatic-indel version 488 
533632 filtered by false-indel version v1 (params: --bam-readcount-version 0.4 --bam-489 
readcount-min-base-quality 15), 2) pindel version 0.533 filtered with pindel false-positive 490 
and vaf filters (params: --variant-freq-cutoff=0.2), 3) VarScan version 2.2.6 30 filtered by 491 
varscan-high-confidence-indel version v1 then false-indel version v1 (params: --bam-492 
readcount-version 0.4 --bam-readcount-min-base-quality 15), and 4) Strelka version 493 
0.4.6.231 (params: isSkipDepthFilters = 1). 494 
 495 
Targeted sequencing for validation 496 
All of the variants (n=6,910) identified in the discovery set excluding those in low 497 
coverage samples were chosen for validation at greater depth as well as exons of a set of 77 498 
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breast cancer related genes of interest (Supplementary Table 2). Probes were designed to 499 
target the variants within 13,372 regions of 6,737 genes covering a total of 2,645,703bp. 500 
Reads were aligned as described above for exome-sequencing. SNVs were detected 501 
using VarScan version 2.2.6 (with parameters --min-var-freq 0.08 --p-value 0.10 --somatic-p-502 
value 0.01 --validation) and filtered by Varscan-high-confidence version v1, then false-503 
positive version v1 (with parameters: --bam-readcount-version 0.4 --bam-readcount-min-504 
base-quality 15). 505 
InDels were detected using the union of 3 callers: GATK somatic-indel version 5336, 506 
pindel version 0.5 (filtered by pindel-somatic-calls version v1, then pindel-read-support 507 
version v1) and VarScan version 2.2.6 (filtered by varscan-high-confidence-indel version v1, 508 
then false-indel version, with parameters: --bam-readcount-version 0.4 --bam-readcount-509 
min-base-quality 15). 510 
In addition to using matched normal for germline detection, sites that were present 511 
in at least 0.1% of the general population according to the 1000 Genomes Project34 or NHLBI 512 
GO Exome Sequencing Project were removed from further analysis. 513 
All somatic events from re-sequencing were manually reviewed using IGV35. 514 
 515 
SNP profile 516 
Samples were confirmed as being derived from the same patient by correlation of 517 
single nucleotide polymorphisms (SNPs, Supplementary Fig. 9) based on the sequencing 518 
data. Therefore, all samples have been profiled based on over 500 SNPs from dbSNP version 519 
138 within the area of the capture panel. The genotypes at genomic position were derived 520 
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using samtools28. SNPRelate36 was used to cluster the samples and generate the 521 
dendrogram using default parameters. 522 
 523 
Subclonal analysis 524 
Clonal architecture was inferred using SciClone version 1.0.47 (params: 525 
minimumDepth=50) using copy number and LOH calls derived from Varscan (params: loh-526 
cutoff=0.95, min-loh-probes=10, min-mapping-quality=10, min-coverage=20. min-segment-527 
size=25, max-segment-size=100, undo.sd=4). Samples with low mutation count failed 528 
clustering and were excluded from the analysis. SciClone plots were annotated with 529 
frequently mutated genes from Supplementary Table 6.  530 
 531 
Comparison to known driver genes 532 
Validated mutations in the baseline and surgery samples were compared to known 533 
driver genes in the DriverDB9 database. Therefore, “breast” tissue was selected as cancer 534 
type and all genes identified by at least 2 tools were downloaded from the website. 535 
 536 
Estimating tumour purity based on WES 537 
For estimating cellularity based on whole exome sequencing data Sequenza v2.1.137 538 
was used. The algorithm was applied for each tumour sample and its matched blood 539 
sample. In brief, it first detects germline mutations in the normal sample and then calculates 540 
the VAF at the same position in the tumour sample. In the second step the tumour versus 541 
normal depth ratio is calculated with GC-content normalization and allele-specific 542 
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segmentation is performed. Based on a probabilistic model applied to segmented data 543 
Sequenza calculates possible solutions for cellularity and ploidy of the tumour. The default 544 
settings were used for all steps, the cellularity with the highest probability was reported. 545 
 546 
Statistical analysis 547 
Unpaired and nonparametric Mann-Whitney test was used to test the differences of 548 
mutation counts between groups. The Wilcoxon signed-rank test was used to test for 549 
differences in the mutation counts of paired samples between baseline and surgery and to 550 
compare the variant allele fractions (VAFs) between baseline and surgery samples. The 551 
associations of TP53 mutation status and HER2 status between the groups were analysed 552 
using Fisher’s exact test. Reported p-values are two-sided and unadjusted; p-value < 0.05 is 553 
considered to be significant in this study. The statistical analyses were conducted in 554 
GraphPad Prism 6 (Graphpad Software Inc.) and R38. 555 
 556 
Data availability 557 
The sequencing data that support this study have been deposited in the European 558 
Genome-phenome Archive (EGA) database under accession code EGAS00001001940. The 559 
remaining data is available in the Article or Supplementary files or available from the 560 
authors upon request. 561 
 562 
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Figure legends:  743 
Fig. 1. CONSORT diagram and mutational landscape.  744 
 745 
Samples were selected in two phases using the same quality criteria. Samples in Phase I (a) 746 
underwent whole exome sequencing (WES) at low coverage for mutation detection 747 
followed by capture-probe sequencing for validation. Our goal was to select the same 748 
number of Controls, good responders and poor responders, but due to the availability of 749 
samples and exclusion criteria, we were not able to identify 20 poor responders, instead 15 750 
and 25 poor responders entered the analysis. In Phase II (b) samples which failed WES (not 751 
shown, see Supplementary Fig. 1) and samples from additional patients without prior WES 752 
were sequenced with the same capture-probe panel as in Phase I. To balance the number of 753 
patients in the responder groups, preferentially poor responders were added. When 754 
samples from Phase I and II combined, a total of 86 patients entered the downstream 755 
analysis, of which 77 are paired samples (see also Table 2). CONSORT diagram is simplified; a 756 
more detailed version can be found in Supplementary Fig. 1. (c) Mutation type of all 757 
validated mutations in the exome of 59 patients from Phase I and (d) number of mutations 758 
in each patient by responder groups. Identical mutations found in the baseline and surgery 759 
sample of the same patients appear once in this Figure only. 760 
 761 
Fig. 2. Differences of mutation counts and treatment effects. 762 
 763 
Analysis on the mutation load of samples with exome-wide mutation profile from Phase I. 764 
(a-b) Poor responder showed significantly more mutations than good responder on baseline 765 
(B) and surgery (S). (c) Also the number of mutations on a per-patient basis (mutations from 766 
B and S samples combined, counting identical mutations once only) was significantly higher 767 
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in poor responders. Median and interquartile ranges are shown as bars. (d) No significant 768 
difference between the B and S mutation counts within responder groups between each of 769 
the 49 paired samples. (e) Good and poor responders showed a significant, but low 770 
reduction of the mean variant allele fractions (VAFs) of single nucleotide variants between B 771 
and S. Whiskers show 95% confidence interval. Significance was tested by Mann-Whitney 772 
test. 773 
 774 
Fig. 3. Intra-tumour heterogeneity. 775 
 776 
Five examples with clear intra-tumour heterogeneity are shown (see Supplementary Fig. 6-8 777 
for plots of all samples). Some patients had clusters present in both samples (P007, P014 778 
and P039), while others had several clusters that were found in either the baseline or 779 
surgery sample (P002 and P046). The variant allele fractions of mutations are shown. Whole 780 
exome sequencing was used for copy-number assessment and only mutations in copy 781 
number neutral regions were plotted. Colours indicate assigned clusters by SciClone 782 
(Methods). Cancer related genes listed in Supplementary Table 4 are labelled in the plots.  783 
 784 
Fig. 4. Frequently mutated genes 785 
Sample matrix for genes with mutations in 10% or more of the patients. All 163 tumour 786 
samples from 86 patients (including 77 pairs) with baseline (B) and surgery (S) sample are 787 
shown. For Phase I samples the bottom row shows if the sample successfully underwent 788 
whole exome sequencing and therefore mutations identified in this sample were added to 789 
the capture-probe panel. The TP53 mutation of P038 and one of each mutation of MLL3 for 790 
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P046 were not identical between B and S. The overall concordance between B and S 791 
samples of patients was 71%. 792 
 793 
Fig. 5. Relation of mutations to Ki67 794 
 (a) Correlation of mutations counts to the Ki67 level was highest for treated samples at 795 
surgery. (b) On the combined set from Phase I and Phase II the Ki67 level of poor responders 796 
was significantly higher for patients with mutated TP53 (mut) than wild-type TP53 (WT). This 797 
was not seen for good responders, although Ki67 level for TP53 mutated patients was higher 798 
on baseline (Supplementary Fig. 11). Significance tested by Mann-Whitney test, red lines 799 
show median and interquartile ranges. 800 
  801 
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Table 1. Clinical data summary of all 86 patients in this study. Patient’s demographics are separated 802 
by poor responder, good responder and Control. All analysis based on somatic mutations within 77 803 
breast cancer related genes are conducted on this set of patients combined from Phase I and II (no 804 
analysis was conducted on Phase II samples only). Analyses on the exome-wide mutational load 805 
were performed on samples from Phase I with whole exome sequencing. The demographics of these 806 
patients only are shown in Supplementary Table 1.   807 
  Response group
  Poor (n=33) Good (n=33) Control (n=20)
  n % n % n %
PgR status   
Positive 20 60.6 26 78.8 16 80.0
Negative 7 21.2 5 15.2 3 15.0
Not known 6 18.2 2 6.1 1 5.0
Histological subtype 
Ductal 27 81.8 24 72.7 17 85.0
Lobular 3 9.1 5 15.2 2 10.0
Mucinous 1 3.0 1 3.0 0 0.0
Mixed ductal and lobular 2 6.1 1 3.0 1 5.0
Not known 0 0.0 2 6.1 0 0.0
Pre-treatment tumour grade 
G1 2 6.1 0 0.0 3 15.0
G2 14 42.4 22 66.7 9 45.0
G3 10 30.3 4 12.1 5 25.0
Not known 7 21.2 7 21.2 3 15.0
No. of involved lymph nodes 
N0 20 60.6 20 60.6 11 55.0
N1-3 7 21.2 11 33.3 6 30.0
N4+ 6 18.2 2 6.1 3 15.0
HER2 status 
Negative 25 75.8 32 97.0 13 65.0
Positive 8 24.2 1 3.0 7 35.0
Pre-treatment tumour size (cm) 
<2 12 36.4 11 33.3 7 35.0
2-5 19 57.6 22 66.7 12 60.0
>5 2 6.1 0 0.0 1 5.0
Surgery tumour size (cm) 
<2 12 36.4 13 39.4 8 40.0
2-5 20 60.6 20 60.6 10 50.0
>5 1 3.0 0 0.0 2 10.0
  Median IQR Median IQR Median IQR
Age at randomization (years) 70 61 - 78 74 62 – 82 70 59 - 76 
Time from randomization to surgery (days) 19 15 - 23 17 15 – 19 18.5 14 - 23.5 
 808 
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Table 2. Summary of available samples in this study. Analyses on the mutational load and 810 
the mutational clusters were performed on Phase I samples with exome sequencing 811 
available. Analyses based on 77 breast cancer related genes were performed on the 812 
combined set of Phase I and II samples. As indicated in the text, some analyses were 813 
performed on patients with paired baseline and surgery samples only. 814 
Summary Total Good Poor Control
Phase I
Samples with mutations discovered by exome- 108 45 26 36
Patients with paired exome-sequencing 49 21 11 17
Patients with exome-seq from either sample 59 24 15 20
Patients with exome-sequencing in baseline 52 22 12 18
Patients with exome-sequencing in surgery 56 23 14 19
      
Phase I and II
Samples with targeted sequencing 163 64 59 40
Patients with targeted sequencing from either sample 86 33 33 20
Patients with paired targeted-sequencing 77 31 26 20
Patients with targeted sequencing in baseline 84 32 32 20
Patients with targeted sequencing in surgery 79 32 27 20
 815 
 816 
 817 
62.71% (2654) Missense
22.97%   (972) Silent
6.12%     (259) Nonsense
5.41%     (229) InDel
1.42%       (60) Splice Site
1.35%       (57) RNA
0.02%         (1) Nonstop
        Total = 4,232
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Fig. 1. CONSORT diagram and mutational landscape.
Samples were selected in two phases using the same quality criteria. Samples in Phase I (a) underwent whole exome 
sequencing (WES) at low coverage for mutation detection followed by capture-probe sequencing for validation. Our goal was 
to select the same number of Controls, good responders and poor responders, but due to the availability of samples and 
exclusion criteria, we were not able to identify 20 poor responders, instead 15 and 25 poor responders entered the analysis. In 
Phase II (b) samples which failed WES (not shown, see Supplementary Fig. 1) and samples from additional patients without 
prior WES were sequenced with the same capture-probe panel as in Phase I. To balance the number of patients in the 
responder groups, preferentially poor responders were added. When samples from Phase I and II combined, a total of 86 
patients entered the downstream analysis, of which 77 are paired samples (see also Table 2). CONSORT diagram is 
simplified, a more detailed version can be found in Supplementary Fig. 1. (c) Mutation type of all validated mutations in the 
exome of 59 patients from Phase I and (d) number of mutations in each patient by responder groups. Identical mutations found 
in the baseline and surgery sample of the same patients appear once in this Figure only.
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Fig. 2. Di erences of mutation counts and treatment e ects.
Analysis on the mutation load of samples with exome-wide mutation 
pro le from Phase I. (a-b) Poor responder showed signi cantly more 
mutations than good responder on baseline (B) and surgery (S). (c) 
Also the number of mutations on a per-patient basis (mutations from 
B and S samples combined, counting identical mutations once only) 
was signi cantly higher in poor responders. Median and interquartile 
ranges are shown as bars. (d) No signi cant di erence between the 
B and S mutation counts within responder groups between each of 
the 49 paired samples. Red lines show median and interquartile 
ranges. (e) Good and poor responders showed a signi cant, but low 
reduction of the mean variant allele fractions (VAFs) of single 
nucleotide variants between B and S. Whiskers show 95% con dence 
interval. Signi cance was tested by Mann-Whitney test.
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Fig. 3. Intra-tumour heterogeneity.
Five examples with clear intra-tumour heterogeneity are shown (see Supplementary Fig. 6-8 for plots of all samples). Some patients had clusters present in 
both samples (P007, P014 and P039), while others had several clusters that were found in either the baseline or surgery sample (P002 and P046). The variant 
allele fractions of mutations are shown. Whole exome sequencing was used for copy-number assessment and only mutations in copy number neutral regions 
were plotted. Colours indicate assigned clusters by SciClone (see Methods). Cancer related genes listed in Supplementary Table 4 are labelled in the plots. 
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Fig. 4. Frequently mutated genes
Sample matrix for genes with mutations in 10% or more of the patients. All 163 tumour samples from 86 patients (including 77 pairs) with baseline (B) and 
surgery (S) sample are shown. For Phase I samples the bottom row shows if the sample successfully underwent whole exome sequencing and therefore 
mutations identified in this sample were added to the capture-probe panel. The TP53 mutation of P038 and one of each mutation of MLL3 for P046 were not 
identical between B and S. The overall concordance between B and S samples of patients was 71%.
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Fig. 5. Relation of mutations to Ki67
(a) Correlation of mutations counts to the Ki67 level was highest for treated 
samples at surgery (Spearman correlation). (b) On the combined set from Phase I 
and Phase II the Ki67 level of poor responders was signi cantly higher for patients 
with mutated TP53 (mut) than wild-type TP53 (WT). This was not seen for good 
responders, although Ki67 level for TP53 mutated patients was higher on baseline 
(Supplementary Fig. 11). Signi cance tested by Mann-Whitney test, red lines show 
median and interquartile ranges.
Table 1. 
n % n % n %
PgR status
Positive 20 60.6 26 78.8 16 80
Negative 7 21.2 5 15.2 3 15
Not known 6 18.2 2 6.1 1 5
Histological subtype
Ductal 27 81.8 24 72.7 17 85
Lobular 3 9.1 5 15.2 2 10
Mucinous 1 3 1 3 0 0
Mixed ductal and lobular 2 6.1 1 3 1 5
Not known 0 0 2 6.1 0 0
Pre-treatment tumour grade
G1 2 6.1 0 0 3 15
G2 14 42.4 22 66.7 9 45
G3 10 30.3 4 12.1 5 25
Not known 7 21.2 7 21.2 3 15
No. of involved lymph nodes
N0 20 60.6 20 60.6 11 55
N1-3 7 21.2 11 33.3 6 30
N4+ 6 18.2 2 6.1 3 15
HER2 status
Negative 25 75.8 32 97 13 65
Positive 8 24.2 1 3 7 35
Pre-treatment tumour size (cm)
<2 12 36.4 11 33.3 7 35
2-May 19 57.6 22 66.7 12 60
>5 2 6.1 0 0 1 5
Surgery tumour size (cm)
<2 12 36.4 13 39.4 8 40
2-May 20 60.6 20 60.6 10 50
>5 1 3 0 0 2 10
Median IQR Median IQR Median IQR
Age at randomization (years) 70 61 - 78 74 62 – 82 70 59 - 76
Time from randomization to sur 19 15 - 23 17 15 – 19 18.5 14 - 23.5
Response group
Poor (n=33) Good (n=33) Control (n=20)
Table 2.
Summary Total Good Poor Control
Samples with mutations discovered by exome-sequenci 108 45 26 36
Patients with paired exome-sequencing 49 21 11 17
Patients with exome-seq from either sample 59 24 15 20
Patients with exome-sequencing in baseline 52 22 12 18
Patients with exome-sequencing in surgery 56 23 14 19
Samples with targeted sequencing 163 64 59 40
Patients with targeted sequencing from either sample 86 33 33 20
Patients with paired targeted-sequencing 77 31 26 20
Patients with targeted sequencing in baseline 84 32 32 20
Patients with targeted sequencing in surgery 79 32 27 20
Phase I
Phase I and II
